ANAHEIM, Calif. – Research presented today at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo shows that a questionnaire-based algorithm predicts the risk of a pregnant woman developing preeclampsia. This method could lower the high maternal death rate in resource-limited countries by identifying women who need treatment for this often fatal condition.
Preeclampsia is a multisystem disorder that can cause devastating complications for mothers and babies, from brain and liver injury in mothers to premature birth. It is one of the top causes of maternal-fetal mortality worldwide, and it disproportionately affects women in resource-limited countries. While preeclampsia is fatal for only 1 out of every million births in the U.K., it is responsible for more than 570 deaths per million births in Ghana. Worse yet, this is considered an average preeclampsia death rate for low- and middle-income countries.
Preeclampsia often kills because healthcare providers aren’t able to monitor pregnant women for its onset. To address this, a research team led by Enoch Anto, a PhD candidate at Edith Cowan University in Perth, Australia, created a simple, low-cost algorithm that identifies pregnant women who are at risk for preeclampsia. A key component of the algorithm is the suboptimal health status questionnaire-25 (SHSQ-25), which assesses a patient’s overall health by asking questions about fatigue levels, cardiovascular health, digestive health, immune health, and mental health. Anto’s professor Wei Wang MD, PhD, initially developed SHSQ-25 to predict diabetes and cardiovascular disease risk, but Anto hypothesized it could also predict preeclampsia risk.
To develop the algorithm, Anto’s team first administered the SHSQ-25 to 498 Ghanaian women who were 10-20 weeks pregnant, in addition to measuring relevant physiological metrics such as magnesium and calcium levels. Based on participants’ questionnaire scores, the researchers classified 49.8% of the women as being in poor overall health (high SHS) and 50.2% as being in good health (low SHS). Ultimately, 61.7% of the high SHS women went on to develop preeclampsia, compared with just 17.6% of the low SHS women. The high SHS women who developed preeclampsia also exhibited significantly lower magnesium and calcium levels, leading the researchers to incorporate these metrics into the predictive algorithm. Overall, the algorithm identified 77.7% of the women who developed preeclampsia.
“Women develop this condition at an outrageous rate in Ghana, but its early clinical signs often go undetected,” Anto said. “Why not try to develop a new approach that identifies clinical manifestations of preeclampsia before it happens? This [algorithm] could … be used to predict hypertensive disorders of pregnancy, thus creating a window of opportunity for predictive, preventive, and personalized medicine.”
AACC Annual Scientific Meeting registration is free for members of the media. Reporters can register online here: https://www.xpressreg.net/register/aacc0819/media/landing.asp
Abstract B-155: Algorithm of Suboptimal Health Status, Serum Magnesium, and Calcium Levels as a Novel Approach for Prediction and Identification of Pregnant Women Likely to Develop Preeclampsia and Adverse Perinatal Complications in a Ghanaian Population will be presented during the following two sessions:
AACC Student Poster Contest (Part 2): Poster Presentations
Monday, August 5
2:15 - 3:30 p.m.
Scientific Poster Session
Wednesday, August 7
9:30 a.m. – 5 p.m. (presenting author in attendance from 12:30 – 1:30 p.m.)
Both sessions will take place at the Anaheim Convention Center in California.
About the 71st AACC Annual Scientific Meeting & Clinical Lab Expo
The AACC Annual Scientific Meeting offers 5 days packed with opportunities to learn about exciting science from August 4-8. Plenary sessions feature the latest research on accelerating the clinical adoption of new biomedical discoveries, the influence of genetics and brain circuitry on behavior, targeted breast cancer treatment, advances in precision medicine, and extremely rapid molecular diagnostic tests.
At the AACC Clinical Lab Expo, more than 800 exhibitors will fill the show floor of the Anaheim Convention Center in California with displays of the latest diagnostic technology, including but not limited to mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation.
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.